- Home
- CRESY vs MYGN Comparison
CRESY vs MYGN Comparison
Compare CRESY & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRESY
- MYGN
- Stock Information
- Founded
- CRESY 1936
- MYGN 1991
- Country
- CRESY Argentina
- MYGN United States
- Employees
- CRESY N/A
- MYGN N/A
- Industry
- CRESY Real Estate
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CRESY Finance
- MYGN Health Care
- Exchange
- CRESY Nasdaq
- MYGN Nasdaq
- Market Cap
- CRESY 615.0M
- MYGN 642.0M
- IPO Year
- CRESY 1997
- MYGN 1995
- Fundamental
- Price
- CRESY $12.33
- MYGN $8.05
- Analyst Decision
- CRESY
- MYGN Hold
- Analyst Count
- CRESY 0
- MYGN 13
- Target Price
- CRESY N/A
- MYGN $13.50
- AVG Volume (30 Days)
- CRESY 308.6K
- MYGN 912.6K
- Earning Date
- CRESY 11-10-2025
- MYGN 11-03-2025
- Dividend Yield
- CRESY 4.87%
- MYGN N/A
- EPS Growth
- CRESY N/A
- MYGN N/A
- EPS
- CRESY 0.12
- MYGN N/A
- Revenue
- CRESY $767,102,963.00
- MYGN $832,900,000.00
- Revenue This Year
- CRESY N/A
- MYGN $0.06
- Revenue Next Year
- CRESY N/A
- MYGN $5.68
- P/E Ratio
- CRESY $9.58
- MYGN N/A
- Revenue Growth
- CRESY N/A
- MYGN 3.83
- 52 Week Low
- CRESY $8.39
- MYGN $3.76
- 52 Week High
- CRESY $14.23
- MYGN $22.92
- Technical
- Relative Strength Index (RSI)
- CRESY 75.24
- MYGN 60.02
- Support Level
- CRESY $8.91
- MYGN $7.98
- Resistance Level
- CRESY $13.52
- MYGN $8.50
- Average True Range (ATR)
- CRESY 0.57
- MYGN 0.35
- MACD
- CRESY 0.32
- MYGN -0.02
- Stochastic Oscillator
- CRESY 74.27
- MYGN 60.80
About CRESY Cresud S.A.C.I.F. y A.
Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.